IMI impact on paediatric medicine - Event
Start Date 10/11/2021About this event
For a long time, paediatric medicine development has largely been neglected, meaning that drugs used in children have not been appropriately tested in paediatric populations. However, European legislation introduced more than 10 years ago, as well as equivalent legislation in the United States, have stimulated research efforts in this area. By 2016, 101 paediatric medicines and 99 new paediatric indications had been authorised by regulators (see figures) and there has been an increase of almost 50% in the number of clinical trials that include child participants. Yet despite these developments, there are still many challenges and unmet medical needs to address, including childhood cancer; a fraction of the number of anti-cancer medicines for kids are authorised compared to those for adults, for example.
Medical innovation has often been slow to trickle down to children and adolescents, and IMI's paediatric research portfolio hopes to change that: we're setting up a sustainable infrastructure for delivering paediatric clinical trials, transforming the way clinical trials are conducted particularly for paediatric rare diseases, building a platform to identify promising molecules to fight paediatric cancer, studying genetic newborn screening for rare diseases, and tackling infectious diseases that plague children, all while placing kids and their families at the centre of research.
This event will provide an opportunity to present that the results already generated by these still ongoing projects.
The target audience for this event includes IMI project members, industry representatives, European Commission representatives, regulators, journalists, members of parliament, parents/children and members of the IMI patient pool, NGOs, funding organisations (also outside Europe), among others.
Register here !
Registration is free but mandatory.
For any questions regarding this event please contact us at imi_events@imi.europa.eu.
Find out more about...
IMI impact on paediatric medicine
Agenda
14:00-14:05 |
Welcome and introduction Nathalie Seigneuret, Senior Scientific Project Manager, IMI |
14:05-14:15 |
The challenge, the vision and the value Solange Corriol-Rohou, Senior Director Regulatory Affairs, AstraZeneca Presentation |
14:15-14:55 |
How IMI projects contribute to advance the paediatric research and development
|
14:55-15:25 |
Q&A time |
15:25-15:30 |
Closing remarks by Claas Röhl, Member of the IMI Scientific Committee and President of NF Kinder |
You can view the recording of all the presentations here.
Meet the speakers
Sr Global Policy Director |
Paediatric Development |
General paediatrician
|
|
Director Preclinical Program |
Member of the IMI |
Moderated by:
Nathalie Seigneuret Senior Scientific Project Manager |